Metoclopramide (4-amino-5-chloro-N-[2-(diethylamino)ethyl]-o-anisamide hydrochloride)
is a non-phenothiazine antiemetic drug which inhibits vomiting caused by either centrallyacting emetics such as apomorphine or local emetics acting on the stomach (Justin-Besancon and Laville, 1964;  Laville, 1964; Malmejac et al., 1964) . Metoclopramide also appears to speed gastric emptying by a direct action within smooth muscle (Jacoby and Brodie, 1967) . As a result, metoclopramide has been introduced as an antiemetic for a wide range of gastrointestinal disorders and as an aid to radiological study of the gastrointestinal tract (Robinson, 1973a) .
While used as an antiemetic, metoclopramide has been reported to produce acute dystonic reactions in approximately 1 % of patients (Robinson, 1973b) . These dyskinesias begin acutely after drug administration, occur most frequently in young patients, and consist of torticollis, trismus, facial spasms, opisthotonos, and oculogyric crises (Borenstein and Bles, 1965; Casteels-Van Daele et al., 1970; De Silva et al., 1973) . They are therefore identical with acute dyskinesias produced by phenothiazine and butyrophenone antipsychotic drugs. The latter drugs are known to block central dopamine receptors (Anden et al., 1970) and therefore frequently produce Parkinsonism when administered chronically (Hornykiewicz, 1973) . The fact that metoclopramide, like the phenothiazines and butyrophenones, produces catalepsy (Costall and Naylor, 1973) and antagonizes the behavioural effects of apomorphine and amphetamine in laboratory animals (Janssen et al., 1967; Hackman et al., 1973; Dolphin et al., 1975) indicates that it, too, may block dopamine receptors important for motor function as well as those involved in vomiting mechanisms (Peng, 1963) .
Primarily because of the occurrence of acute dyskinesias, the use of metoclopramide in Parkinson's disease has been discouraged (Carter, 1973; Hildick-Smith, 1973) . Strikingly, however, signs of Parkinsonism such as akinesia and rigidity have rarely been described as acute reactions to metoclopramide (Borenstein and Bles, 1965) Subjects were treated as outpatients with metoclopramide, 30 mg daily given in three divided doses. Assessments for total disability, tremor, rigidity, akinesia, and posture were made at the start of treatment and at four week intervals according to a scoring method described previously (Marsden et al., 1973) . Subjective impressions and adverse effects were recorded at each visit. In four patients the dose of metoclopramide was increased to 60 mg daily, twice the normal antiemetic dose, during the last four weeks of treatment.
CONTROLLED TRIAL OF METOCLOPRAMIDE, PIMOZIDE, AND PROMETHAZINE Twenty-four patients with Parkinson's disease (23 idiopathic and one postencephalitic; 15 men and nine women; mean age (Siegel, 1956 ). § NS.
placebo, and after metoclopramide showed no significant difference (Table 2 ). The incidence and severity of levodopa-induced involuntary movements was unchanged and acute dyskinesias did not appear. One patient complained of increased gait disturbance and a second of 'talking rubbish' while receiving metoclopramide but objective changes were not observed.
Pimozide Seven of ten patients completed the trial. One patient was dropped because of poor clinic attendance, while in two others pimozide was discontinued after two weeks because of intolerable worsening of Parkinsonism. In these two patients disability scores after two rather than four weeks of active drug were retained for statistical analysis. In two other patients the daily dose of pimozide could not be raised above 1 mg because of increased Parkinsonism. The remaining five patients reached 4 mg daily with signs of worsening being obvious in two cases. When mean total disability scores after pimozide were compared with those after placebo a significant increase in Parkinsonism was observed (Table 2) . Disability subscores for akinesia and rigidity showed the greatest change. Subjectively, symptoms of increasing Parkinsonism were often prominent with patients reporting increased gait disturbance, falling, and a general 'slowing down'. Among nine patients with levodopainduced involuntary movements, various combinations of chorea, orofacial dyskinesia, and dystonia were abolished in five and significantly reduced in a sixth patient (Table 2) . No change in involuntary movements occurred after placebo. In four of these six patients abolition of involuntary movements was associated with a significant increase in Parkinsonism which occurred simultaneously, while in two cases Parkinsonism did not change. Conversely, two patients showing increased Parkinsonism showed no change in involuntary movements.
Promethazine Four of six patients completed the trial. One patient completed placebo but discontinued promethazine after three weeks because of drowsiness and blurred vision; a second completed promethazine but discontinued placebo after two weeks because of nausea, gait disturbance, and increased tremor. In these two cases disability scores after two rather than four weeks of the incomplete periods were used for statistical analysis. Comparison of mean total disability scores and disability subscores before treatment, after placebo, and after promethazine showed no significant change ( Table 2) . The incidence and severity of levodopa-induced involuntary movements also remained unchanged.
DISCUSSION
Behavioural studies in rodents suggest that metoclopramide blocks striatal dopamine receptors with about one-tenth the potency ofpimozide (Dolphin et al., 1975) . The fact that metoclopramide is a potent stimulator of prolactin release in humans (McNeilly et al., 1974) is similar to the effect of phenothiazines (Turkington, 1972 ) and suggests blockade of dopamine receptors within the median eminence of the hypothalamus. As already indicated, metoclopramide blocks the action of apomorphine, a known dopamine receptor stimulator, in the medullary chemoreceptor trigger zone (Malmejac et al., 1964) .
Drugs which block dopamine receptors, such as phenothiazines or butyrophenones, reverse the anti-Parkinsonism effect of levodopa and abolish levodopa-induced involuntary movements (Klawans and Weiner, 1974) . In this study pimozide was quite potent in its ability to increase Parkinsonism and abolish levodopainduced involuntary movements, an effect similar to that of haloperidol (Klawans and Weiner, 1974) . Metoclopramide, by contrast, given in larger than antiemetic doses and up to 15 times the dose of pimozide, resembled promethazine in failing to increase signs of Parkinsonism or reverse levodopa-induced involuntary movements in both a short double-blind study or the more prolonged open trial. It is interesting to note that metoclopramide is also devoid of significant antipsychotic activity (Borenstein and Bles, 1965) . Since drugs which interfere with striatal dopaminergic mechanisms are usually effective as antipsychotic drugs (Anden et al., 1970; Matthysse, 1973) , this too has been an unexpected finding.
The mechanism of drug-induced acute dyskinesias is unknown. Antipsychotic drugs which produce acute dyskinesias also produce Parkinsonism after chronic administration. Although this may suggest that dopamine receptor blockade is important for the acute dyskinesias as well as for drug induced Parkinsonism, this is entirely speculative. The capacity of metoclopramide to produce acute dyskinesias but fail to produce Parkinsonism in either normal subjects or in patients with pre-existing Parkinson's disease is a unique pharmacological property. Phenothiazines which, like metoclopramide, have antiemetic properties but do not produce Parkinsonism (such as promethazine) also do not produce acute dyskinesias.
Several simple explanations for our findings might be offered. Failure to gain access to striatal receptors in the dose used, variability in effect of metoclopramide on different central dopamine receptors, or some unrecognized pharmacological property which protects against production ofParkinsonism might be considered. This study offers indirect evidence, however, that the mechanism for drug-induced acute dyskinesias may be entirely separate from interference with striatal dopaminergic mechanisms. Recent reports that fenfluramine occasionally produces acute dystonic reactions (Sananman, 1974) 
